• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Biol Chem . Interferon at the crossroads of SARS-CoV-2 infection and COVID-19 disease

tetano

Editor, Senior Moderator
J Biol Chem


. 2023 Jun 24;104960.
doi: 10.1016/j.jbc.2023.104960. Online ahead of print. Interferon at the crossroads of SARS-CoV-2 infection and COVID-19 disease

Charles E Samuel[SUP] 1 [/SUP]



Affiliations
Abstract

A novel coronavirus now known as SARS-CoV-2 emerged during late 2019, possibly following zoonotic crossover from a coronavirus present in bats. This virus was identified as the pathogen responsible for the severe respiratory disease, coronavirus disease-19 (COVID-19), that as of May, 2023, has killed an estimated 6.9 million people globally according to the World Health Organization. The interferon (IFN) response, the cornerstone of antiviral innate immunity, plays a key role in determining the outcome of infection by SARS-CoV-2. This review considers evidence that SARS-CoV-2 infection leads to IFN production; that virus replication is sensitive to IFN antiviral action; the molecular mechanisms by which the SARS-CoV-2 virus antagonizes IFN action; and how genetic variability of SARS-CoV-2 and the human host affects the IFN response at the level of IFN production or action or both. Taken together, current understanding suggests that deficiency of an effective IFN response is an important determinant underlying some cases of critical COVID-19 disease, and that IFNλ and IFNα/β have potential as therapeutics for treatment of SARS-CoV-2 infection.

Keywords: RIG-like receptor; Toll-like receptor; coronavirus; innate immunity; interferon; viral immunology.

 
Back
Top Bottom